Cuál es el precio por Nabriva Therapeutics plc (NBRV)

Precio por Nabriva Therapeutics plc (NBRV) es de$0.63

Cuál es la capitalización de mercado por Nabriva Therapeutics plc (NBRV)

Capitalización de mercado por Nabriva Therapeutics plc (NBRV) es $284.20K

Nabriva Therapeutics plc (NBRV) Precio y Capitalización de Mercado

Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.

Precio por NBRV	Activo B	Capital del mercado en B	Resultados
$12,124,540 $284.20K	NVDA	$5.470T	+1,924,530,116.78%
$9,902,333 $284.20K	AAPL	$4.467T	+1,571,798,808.82%
$9,253,527 $284.20K	GOOG	$4.174T	+1,468,813,723.90%
$8,202,107 $284.20K	MSFT	$3.700T	+1,301,921,721.47%
$6,327,334 $284.20K	AMZN	$2.854T	+1,004,338,657.17%

Precio por NBRV

Activo B

Capital del mercado en B

Resultados

$12,124,540 $284.20K